An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 Before Each Meal (q.a.c) in Subjects With Type 2 Diabetes Being Treated With Basal Insulin

A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.

Inclusion Criteria:

• Male or female (of non-childbearing potential) between 18 to 70 years of age
• Diagnosed with Type 2 Diabetes and currently being treated with basal insulin
• Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules

Exclusion Criteria:

• History of Type 1 diabetes
• Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start
• History of severe hypoglycemia
• Allergic to insulin